NCT06272630View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of DWJ1464 in Patients with Chronic Liver Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

263

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

March 29, 2024

Study Completion Date

March 29, 2024

Conditions
Chronic Liver Disease
Interventions
DRUG

DWJ1464

DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week

DRUG

Placebo of DWJ1464

Placebo of DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week

Trial Locations (1)

04401

SoonChunHyang University Seoul Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY